50 related articles for article (PubMed ID: 15782134)
1. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints.
Levesque AA; Kohn EA; Bresnick E; Eastman A
Oncogene; 2005 May; 24(23):3786-96. PubMed ID: 15782134
[TBL] [Abstract][Full Text] [Related]
2. A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides.
Agarwal ML; Agarwal A; Taylor WR; Chernova O; Sharma Y; Stark GR
Proc Natl Acad Sci U S A; 1998 Dec; 95(25):14775-80. PubMed ID: 9843965
[TBL] [Abstract][Full Text] [Related]
3. p53 oligomerization status as an indicator of sensitivity of p53-wildtype neuroblastomas to the combination of DNA damaging agent and Chk1 inhibitor.
Levesque AA; Pappalardo RM; Puli P; Enzor LA; Angeles C
PLoS One; 2022; 17(2):e0263463. PubMed ID: 35143532
[TBL] [Abstract][Full Text] [Related]
4. Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.
Zhao X; Kim IK; Kallakury B; Chahine JJ; Iwama E; Pierobon M; Petricoin E; McCutcheon JN; Zhang YW; Umemura S; Chen V; Wang C; Giaccone G
Mol Oncol; 2021 Apr; 15(4):1130-1145. PubMed ID: 33320980
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.
Hsu WH; Zhao X; Zhu J; Kim IK; Rao G; McCutcheon J; Hsu ST; Teicher B; Kallakury B; Dowlati A; Zhang YW; Giaccone G
J Thorac Oncol; 2019 Jun; 14(6):1032-1045. PubMed ID: 30771522
[TBL] [Abstract][Full Text] [Related]
6. Exploiting the p53 Pathway for Therapy.
Cheok CF; Lane DP
Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 28193768
[TBL] [Abstract][Full Text] [Related]
7. Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
Min DJ; He S; Green JE
Anticancer Res; 2016 Jun; 36(6):2649-57. PubMed ID: 27272773
[TBL] [Abstract][Full Text] [Related]
8. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
Alsubhi N; Middleton F; Abdel-Fatah TM; Stephens P; Doherty R; Arora A; Moseley PM; Chan SY; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Martin SG; Curtin NJ; Madhusudan S
Mol Oncol; 2016 Feb; 10(2):213-23. PubMed ID: 26459098
[TBL] [Abstract][Full Text] [Related]
9. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
Liu Y; Kwiatkowski DJ
Mol Cancer Ther; 2015 Jan; 14(1):174-82. PubMed ID: 25349305
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
Montano R; Thompson R; Chung I; Hou H; Khan N; Eastman A
BMC Cancer; 2013 Dec; 13():604. PubMed ID: 24359526
[TBL] [Abstract][Full Text] [Related]
11. p53 Dimers associate with a head-to-tail response element to repress cyclin B transcription.
Lipski R; Lippincott DJ; Durden BC; Kaplan AR; Keiser HE; Park JH; Levesque AA
PLoS One; 2012; 7(8):e42615. PubMed ID: 22905155
[TBL] [Abstract][Full Text] [Related]
12. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.
Jacquemont C; Simon JA; D'Andrea AD; Taniguchi T
Mol Cancer; 2012 Apr; 11():26. PubMed ID: 22537224
[TBL] [Abstract][Full Text] [Related]
13. Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors.
Chang LJ; Eastman A
Cell Cycle; 2012 May; 11(9):1818-26. PubMed ID: 22510560
[TBL] [Abstract][Full Text] [Related]
14. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
[TBL] [Abstract][Full Text] [Related]
15. Selective killing of p53-deficient cancer cells by SP600125.
Jemaà M; Vitale I; Kepp O; Berardinelli F; Galluzzi L; Senovilla L; Mariño G; Malik SA; Rello-Varona S; Lissa D; Antoccia A; Tailler M; Schlemmer F; Harper F; Pierron G; Castedo M; Kroemer G
EMBO Mol Med; 2012 Jun; 4(6):500-14. PubMed ID: 22438244
[TBL] [Abstract][Full Text] [Related]
16. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Montano R; Chung I; Garner KM; Parry D; Eastman A
Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of methylsulfonylmethane on gastrointestinal (AGS, HepG2, and KEYSE-30) cancer cell lines.
Jafari N; Bohlooli S; Mohammadi S; Mazani M
J Gastrointest Cancer; 2012 Sep; 43(3):420-5. PubMed ID: 21626237
[TBL] [Abstract][Full Text] [Related]
18. Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells.
Mao P; Hever MP; Niemaszyk LM; Haghkerdar JM; Yanco EG; Desai D; Beyrouthy MJ; Kerley-Hamilton JS; Freemantle SJ; Spinella MJ
J Biol Chem; 2011 Jun; 286(22):19381-91. PubMed ID: 21489989
[TBL] [Abstract][Full Text] [Related]
19. Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation.
Varghese B; Swaminathan G; Plotnikov A; Tzimas C; Yang N; Rui H; Fuchs SY
Mol Endocrinol; 2010 Dec; 24(12):2356-65. PubMed ID: 20962042
[TBL] [Abstract][Full Text] [Related]
20. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
Fracasso PM; Williams KJ; Chen RC; Picus J; Ma CX; Ellis MJ; Tan BR; Pluard TJ; Adkins DR; Naughton MJ; Rader JS; Arquette MA; Fleshman JW; Creekmore AN; Goodner SA; Wright LP; Guo Z; Ryan CE; Tao Y; Soares EM; Cai SR; Lin L; Dancey J; Rudek MA; McLeod HL; Piwnica-Worms H
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1225-37. PubMed ID: 20694727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
